drugset / Trial / NCT00496028

Phase I Study in Patients With Solid Tumours

NCT00496028

Phase 1 Completed 148 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.

Timeline

Start
2007-03
Primary completion
2010-01
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Paclitaxel Small molecule Intravenous
Subject saracatinib Small molecule Oral

Indications